SCHEMBL6955347

SCHEMBL6955347

CSc1nc(NCCN2CCOCC2)c(C#N)c(N2CCc3ccccc3CC2)n1

nearest known ligand 0.51

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
LMNA P02545 1/20 0.51
KDM4E B2RXH2 9/20 0.46
ALDH1A1 P00352 8/20 0.46
HPGD P15428 4/20 0.46
HSD17B10 Q99714 3/20 0.46
ACHE P22303 1/20 0.44
TLR9 Q9NR96 5/20 0.44
GAA P10253 3/20 0.44
TSHR P16473 2/20 0.44
CASP1 P29466 2/20 0.44
GLA P06280 1/20 0.44
CYP1A2 P05177 2/20 0.44
CYP3A4 P08684 2/20 0.44
CYP2D6 P10635 2/20 0.44
CYP2C19 P33261 2/20 0.44
CLK4 Q9HAZ1 2/20 0.44
NPSR1 Q6W5P4 1/20 0.44
POLB P06746 2/20 0.43
CASP7 P55210 1/20 0.43
USP2 O75604 1/20 0.42

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL6949245 0.84 KDM4E (0.46) LMNAKDM4EALDH1A1HSD17B10GAA
SCHEMBL6949089 0.82 MKNK1 (0.40) LMNAKDM4EALDH1A1HPGDHSD17B10
SCHEMBL6949195 0.82 LMNA (0.46) LMNAKDM4EALDH1A1HPGDHSD17B10
SCHEMBL6949437 0.80 KDM4E (0.41) LMNAKDM4EALDH1A1HPGDHSD17B10
SCHEMBL6951885 0.78 ALDH1A1 (0.46) LMNAKDM4EALDH1A1HPGDHSD17B10
SCHEMBL6949377 0.74 MEN1 (0.42) LMNAKDM4EALDH1A1HPGDHSD17B10
SCHEMBL6948665 0.74 KDM4E (0.48) LMNAKDM4EALDH1A1HPGDHSD17B10
SCHEMBL6956595 0.74 KMT2A (0.45) LMNAKDM4EALDH1A1HPGDHSD17B10
SCHEMBL4425800 0.71 ALDH1A1 (0.44) LMNAKDM4EALDH1A1HSD17B10GAA
SCHEMBL6949790 0.69 ALDH1A1 (0.41) LMNAKDM4EALDH1A1HPGDHSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1074549-B1 Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors HOFFMANN LA ROCHE (CH) 2003-11-19 EP disclosed
US-6218385-B1 FOR THERAPY OR PROPHYLAXIS OF ACUTE AND/OR CHRONIC NEUROLOGICAL DISORDERS SUCH AS EPILEPSY, STROKE, CHRONIC AND ACUTE PAIN, PSYCHOSIS, SCHIZOPHRENIA, ALZHEIMER'S DISEASE, COGNITIVE DISORDERS AND MEMORY DEFICITS HOFFMANN-LA ROCHE INC. 2001-04-17 US disclosed
EP-1074549-A2 Tetrahydro-benzo(d)azepines and their use as antagonists at metabotropic glutamate receptors F. HOFFMANN-LA ROCHE AG (CH) 2001-02-07 EP disclosed